Close

Production & Manufacturing

Pharmatek adds spray drying to drug manufacturing capabilities

Pharmatek Laboratories, a pharmaceutical chemistry development company, has added spray drying to its drug formulation and manufacturing capabilities.Pharmatek has acquired a Buchi B-290 Mini Spray Dryer for formulation feasibility studies and small-scale clinical manufacture. The technology...

APP Pharmaceuticals Announces Agreement with Teva Pharmaceuticals to Manufacture and Market Gemcitabine HCI for Injection

APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced that it has entered into a commercialization, manufacture and supply agreement with Teva Pharmaceutical USA, Inc., a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd.,...

Nycomed to acquire of majority stake in Guangdong Techpool Bio-Pharma

Nycomed announced that it is significantly expanding its presence in China through the acquisition of a majority stake in Guangdong Techpool Bio-Pharma Co., Ltd. (Techpool), a fast-growing Chinese bio-pharmaceutical company based in Guangdong. Techpool, founded in 1993, specialises in...

Merck’s Investigational Medicine Boceprevir Achieved Significantly Higher SVR Rates

Merck reported that final results from two pivotal Phase III studies of boceprevir, its investigational oral hepatitis C protease inhibitor, demonstrated significantly higher sustained virologic response (SVR)1 rates in adult patients who previously failed treatment (treatment-failure; HCV RESPOND-2) and...

Biocon and Pfizer Enter Into Global Commercialization Agreement-Deliver Essential Insulin Treatments to Diabetes Patients Worldwide

Biocon, Asia's premier biotechnology company, and Pfizer Inc., the world's leading biopharmaceutical company, today announced that they have entered into a strategic global agreement for the worldwide commercialization of Biocon's biosimilar versions of Insulin and Insulin analog products:  Recombinant...

European vaccine development moves forward

The European Vaccine Initiative, a product development partnership supporting the development of vaccines against diseases of poverty, has brought together to Brussels manufacturers, biotech companies, public/academic researchers, and funding agencies to identify the gaps in vaccine research and development...

Novartis announces agreement to develop influenza vaccines using revolutionary synthetic genomics technology

Novartis announced today an agreement with Synthetic Genomics Vaccines Inc. (SGVI) to apply "synthetic genomics" technologies to accelerate the production of the influenza seed strains required for vaccine manufacturing. The seed strain is the starter culture of a virus,...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read